A detailed history of Royce & Associates LP transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Royce & Associates LP holds 6,090 shares of LGND stock, worth $693,042. This represents 0.01% of its overall portfolio holdings.

Number of Shares
6,090
Previous 11,086 45.07%
Holding current value
$693,042
Previous $934,000 34.69%
% of portfolio
0.01%
Previous 0.01%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$82.7 - $110.11 $413,169 - $550,109
-4,996 Reduced 45.07%
6,090 $610,000
Q2 2024

Aug 13, 2024

SELL
$68.53 - $87.91 $276,724 - $354,980
-4,038 Reduced 26.7%
11,086 $934,000
Q1 2024

May 13, 2024

SELL
$68.64 - $89.2 $345,739 - $449,300
-5,037 Reduced 24.98%
15,124 $1.11 Million
Q4 2023

Feb 12, 2024

BUY
$49.57 - $72.63 $369,296 - $541,093
7,450 Added 58.61%
20,161 $1.44 Million
Q3 2023

Nov 09, 2023

BUY
$58.86 - $72.67 $372,289 - $459,637
6,325 Added 99.04%
12,711 $761,000
Q2 2023

Aug 07, 2023

BUY
$69.53 - $79.33 $444,018 - $506,601
6,386 New
6,386 $460,000
Q1 2020

May 12, 2020

SELL
$63.37 - $107.88 $28,516 - $48,546
-450 Closed
0 $0
Q4 2019

Feb 06, 2020

SELL
$96.94 - $113.59 $12,408 - $14,539
-128 Reduced 22.15%
450 $47,000
Q3 2019

Nov 13, 2019

BUY
$86.25 - $120.16 $22,252 - $31,001
258 Added 80.63%
578 $58,000
Q2 2019

Aug 12, 2019

BUY
$107.38 - $129.34 $2,147 - $2,586
20 Added 6.67%
320 $37,000
Q1 2019

May 09, 2019

SELL
$105.93 - $142.47 $1.24 Million - $1.67 Million
-11,700 Reduced 97.5%
300 $38,000
Q4 2018

Feb 11, 2019

BUY
$128.36 - $272.13 $1.54 Million - $3.27 Million
12,000 New
12,000 $1.63 Million
Q1 2018

May 14, 2018

SELL
$138.63 - $182.62 $9,704 - $12,783
-70 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$128.36 - $147.04 $1,026 - $1,176
8 Added 12.9%
70 $10,000
Q3 2017

Nov 13, 2017

BUY
$120.91 - $137.94 $7,496 - $8,552
62
62 $8,000

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.92B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Royce & Associates LP Portfolio

Follow Royce & Associates LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royce & Associates LP, based on Form 13F filings with the SEC.

News

Stay updated on Royce & Associates LP with notifications on news.